Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06368921
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-09
Brief Title:
A Study of Recombinant Oncolytic Virus M1VRT106 in Patients With Solid Tumors
Sponsor:
Guangzhou Virotech Pharmaceutical Co Ltd
Organization:
Guangzhou Virotech Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase I Clinical Study to Evaluate the Safety Tolerability Biodistribution Characteristics Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection VRT106 in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 VRT106 in patients with locally advancedmetastatic solid tumors
Detailed Description:
This study is an open-label dose-escalation clinical study which aims to evaluate the safety and tolerability of IT injections of VRT106 in subjects with locally advancedmetastatic solid tumors as well as evaluating the biological distribution characteristics and biological effects of VRT106 ie virus tissue distribution and shedding characteristics evaluating immunogenicity of VRT106 and preliminarily exploring the anti-tumor effects of VRT106
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None